Clinical Trials Logo

HBV clinical trials

View clinical trials related to HBV.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05063071 Active, not recruiting - HBV Clinical Trials

Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant

Start date: July 29, 2021
Phase: Phase 4
Study type: Interventional

TAF treatment for HBV prophylaxis could lead to significant reduction in ALT and significant improvement in renal function. However, data are scarce regarding to TAF monotherapy without HBIG for HBV prophylaxis in post orthotopic liver transplant with HBV-related disease. This study is based on a real-world, multi-center, prospective study to assess the effectiveness and safety of TAF for HBV prophylaxis, which will fill in gaps with TAF monotherapy without HBIG in post liver transplant.

NCT ID: NCT03158818 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Chronic Hepatitis B Virus Infection in Zambia

HUTCH
Start date: August 23, 2016
Phase:
Study type: Observational

Chronic hepatitis B virus infection is a common condition in Zambia. Among Zambian blood donors, up to 8% are chronically infected with HBV. Despite the burden, awareness of HBV is low in Zambia and the Ministry of Health is in early stages of development of guidelines for HBV screening, treatment, and prevention. The purpose of this clinical cohort study is to characterize the clinical features of chronic HBV infection at UTH and describe treatment and care outcomes. The investigators will enroll 500 adults and follow the cohort for up to 5 years to assess short and long-term viral, serologic, and liver outcomes such as cirrhosis and liver cancer.

NCT ID: NCT02344680 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Liver Fibrosis in Zambian HIV-HBV Co-infected Patients

Start date: October 2015
Phase:
Study type: Observational

In this study the investigators will determine risk factors for liver fibrosis among HIV-HBV co-infected patients in Lusaka, Zambia, and assess the long-term effectiveness of antiretroviral drugs in the prevention and/or reduction of liver disease.